Aspect Biosystems and Novo Nordisk Expand Partnership for Curative Diabetes Medicines

Novo Nordisk and Aspect Biosystems have entered a new phase of their partnership to develop curative medicines for diabetes. Aspect will lead development, manufacturing, and commercialization, while Novo Nordisk will have defined rights to expand its role at a later stage. Novo Nordisk will make an additional equity investment in Aspect and provide research funding to advance these potentially curative therapies.